Compare SOTK & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | IFRX |
|---|---|---|
| Founded | 1975 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 66.0M |
| IPO Year | 1995 | 2017 |
| Metric | SOTK | IFRX |
|---|---|---|
| Price | $4.94 | $2.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 32.9K | ★ 3.0M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $20,909,315.00 | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $59.31 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.23 | $0.74 |
| 52 Week High | $5.70 | $2.95 |
| Indicator | SOTK | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 56.28 |
| Support Level | $3.88 | $0.96 |
| Resistance Level | $5.15 | $2.95 |
| Average True Range (ATR) | 0.32 | 0.22 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 35.03 | 20.86 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.